Presentations

Corporate Presentation and Research Reports

Corporate Presentation and Research Reports

Corporate Presentation

MediciNova Corporate Presentation – March 15, 2024

Zacks Research Reports

MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers – February 29, 2024

MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO – November 27, 2023

MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model – September 29, 2023

MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury – August 21, 2023

MNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech – May 30, 2023

MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled – February 27, 2023

MNOV: Well Financed to Get Through Tough Market Conditions – November 18, 2022

MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway – August 19, 2022

MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome – June 13, 2022

MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia – May 25, 2022

MNOV: Genzyme Patent Litigation Could Lead to Significant Payout – April 6, 2022

MNOV: Ibudilast Identified as Promising Development Candidate in Alcohol Use Disorder and Degenerative Cervical Myelopathy – March 1, 2022

MNOV: Addition of MN-166 to PD-1 Treatment Extends Survival in Preclinical GBM Model – November 23, 2021

MNOV: Animal Trials Commence Testing MN-166 as an MCM – August 16, 2021

MNOV: Positive Results for MN-166 in Phase 2 AUD Trial – June 22, 2021

MNOV: Phase 3 ALS Trial Ongoing – May 28, 2021

MNOV: Milestone Payments from Legacy Gene Therapy Assets – April 26, 2021

MNOV: BARDA Contract to Support Development of MN-166 in ARDS – March 15, 2021

MNOV: $20M Investment to Fund Multiple Programs – January 25, 2021

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients – July 2, 2020

MNOV: Multiple ‘Shots on Goal’ Provide Substantial Potential Upside – May 1, 2020

MNOV: MN-166 to be Developed as a Treatment for Severe Pneumonia and Acute Respiratory Distress Syndrome – March 12, 2020

MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity – February 25, 2020

MNOV: Phase 3 Trial Initiated for MN-166 in ALS – October 30, 2019

MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium – August 14, 2019